Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 9, 2009

Otsuka Inks Six-Month Extension to Research Deal with MethylGene in Ocular Diseases

  • Otsuka Pharmaceutical has extended its research collaboration related to ocular diseases with MethylGene for an additional six months. Otsuka will provide $625,000 to fund research until the end of March 2010. The company will also make a $1.5 million equity investment in MethylGene by the end of October. The current agreement also allows Otsuka to further prolong the collaboration beyond this initial six-month period.

    The partnership, which has already resulted in lead compounds, will focus on identifying more leads and optimizing the molecules. MethylGene will continue to design, synthesize, characterize, and screen small molecule kinase inhibitors that treat ocular diseases excluding cancer. Otsuka will provide additional assistance in the scale-up of selected compounds and preclinical development in multiple in vivo settings for both efficacy and safety.

    The original alliance was formed in March 2008, and MethylGene received $2 million up front. Achievement of development, regulatory, commercialization, and sales milestones would trigger $50.5 million in additional payments. Otsuka remains solely responsible for the clinical development and global commercialization and will pay MethylGene royalties.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »